Overview

A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose Weight

Status:
ACTIVE_NOT_RECRUITING

Trial end date:
2026-04-21

Target enrollment:

Participant gender:

Summary

This study will look at how well CagriSema helps people with excess body weight lose weight. CagriSema is a new medicine developed by Novo Nordisk that combines cagrilintide and semaglutide. CagriSema cannot yet be prescribed by doctors. In the study, participant will either get CagriSema or dummy medicine and which treatment participant get is decided by chance. The study will last for about 1½ years for each participant.

Phase:

PHASE3

Details

Lead Sponsor:

Novo Nordisk A/S

Treatments:

cagrilintide
semaglutide